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Identification of differentially expressed 
lncRNAs in metformin resistant SH-SY5Y 
neuroblastoma cells 
 
Only 1.2% of the total human DNA codes for proteins, with the rest 
only being transcribed into regulatory RNA, known as non-coding RNA. 
Long non-coding RNAs (lncRNAs) are non-coding RNAs that have no or 
limited protein-coding potential, are >200nt in length and include- among 
other categories- long/large intergenic/intervening RNAs (lincRNAs), 
intronic lncRNAs, natural antisense transcripts (NATs) and pseudogenes. 
lncRNAs are key regulators of several cellular processes and have been 
associated with a variety of diseases, including cancer. Metformin (N,N-
dimethylbiguanide) is an oral biguanide already in clinical use against 
diabetes, and has also been suggested to decrease incidence of various 
cancers, including neuroblastoma, the most common extracranial 
paediatric cancer arising at the sympathetic nervous system. 
The present study aimed at assessing the differential expression of 
protein coding and, primarily, non-protein-coding RNAs between control 
untreated SH-SY5Y neuroblastoma cells and cells resistant to 3mM 
Metformin via a paired-end RNA sequencing approach. 
In the first data set (untreated cells compared to cells resistant to 3mM 
Metformin), out of 13741 genes measured, 7855 genes were found to be 
differentially expressed with 108 of them falling within the lncRNA 
category. Among these 33 comprise lincRNAs, 24 are NATs and 18 
pseudogenes. In the second data set (untreated cells compared to cells 
treated with 20mM Metformin) 13481 genes were tested, of which 5652 
showed perturbed expression. Among them, 86 belong to the lncRNA 
category, and in particular 33 are lincRNAs, 19 are NATs and 13 are 
pseudogenes. Interestingly, 34 of the assessed lncRNAs display 
differential expression in both data sets. The results were obtained using a 
threshold of 0.05 for statistical significance (p-value) and a log fold 
change of expression with absolute value of at least 0.6. 
Neuroblastoma cells’ response to Metformin, as well as the acquisition 
of resistance to the drug, trigger the differential expression of a great 
diversity of lncRNAs. Given that Metformin is an appealing and promising 
therapeutic approach against neuroblastoma, these lncRNAs could in turn 
be used as molecular biomarkers towards better prediction, prognosis and 
diagnosis of the disease. Moreover, such an approach would be of interest 
as part of a combination therapy. 
